Sana Biotechnology Files 8-K on Financials
Ticker: SANA · Form: 8-K · Filed: 2025-08-11T00:00:00.000Z
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
Sana Bio dropped an 8-K on Aug 11th detailing financials - check it out.
AI Summary
Sana Biotechnology, Inc. filed an 8-K on August 11, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the earliest event reported as of August 11, 2025. The company is incorporated in Delaware and headquartered in Seattle, Washington.
Why It Matters
This 8-K filing provides an update on Sana Biotechnology's financial status and operational results, which is crucial information for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not appear to contain any new material events or risks.
Key Players & Entities
- Sana Biotechnology, Inc. (company) — Registrant
- August 11, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Seattle, Washington (location) — Principal executive offices
- (206) 701-7914 (phone_number) — Registrant's telephone number
FAQ
What specific financial information is being reported in this 8-K filing?
The filing indicates it covers 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is August 11, 2025.
Where is Sana Biotechnology, Inc. headquartered?
Sana Biotechnology, Inc.'s principal executive offices are located at 188 East Blaine Street, Suite 400, Seattle, Washington 98102.
What is the company's state of incorporation?
The company is incorporated in Delaware.
What is the SEC file number for Sana Biotechnology, Inc.?
The SEC file number for Sana Biotechnology, Inc. is 001-39941.
Filing Stats: 510 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2025-08-11 16:08:34
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share SANA The Nasdaq
Filing Documents
- sana-20250811.htm (8-K) — 54KB
- sana-ex99_1.htm (EX-99.1) — 321KB
- 0001770121-25-000009.txt ( ) — 511KB
- sana-20250811.xsd (EX-101.SCH) — 31KB
- sana-20250811_htm.xml (XML) — 5KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On August 11, 2025, Sana Biotechnology, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release of Sana Biotechnology, Inc. dated August 11, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SANA BIOTECHNOLOGY, INC. Date: August 11, 2025 By: /s/ Susan Wyrick Susan Wyrick Acting Chief Financial Officer (Principal Accounting Officer)